|Bid||124.85 x 1000|
|Ask||124.98 x 800|
|Day's Range||122.05 - 125.20|
|52 Week Range||117.64 - 189.00|
|Beta (5Y Monthly)||0.94|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 21, 2022 - Feb 25, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||204.05|
Subscribe to Yahoo Finance Plus to view Fair Value for JAZZLearn more
Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that six company-sponsored Epidiolex® (cannabidiol) oral solution presentations, including one late-breaking abstract, will be debuted at the upcoming 2021 American Epilepsy Society (AES) annual meeting, which will be held December 3 to 7, 2021 in Chicago, IL.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the first patient was enrolled in a Phase 3 clinical trial evaluating Zepzelca® (lurbinectedin) in combination with the PD-L1 inhibitor Tecentriq® (atezolizumab) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC). The trial, IMforte, conducted in collaboration with F. Hoffmann-La Roche Ltd, will measure the progression-free survival and overall survival benefits of Zepzelca and Tece